In this Episode of No Spotlight Needed, Sheetal sits down with Dorothy Gemmell, a five time Chief Commercial Officer who helped scale multiple high growth healthcare businesses.

No Spotlight Needed Website: https://www.nospotlightneeded.com/

Dorothy shares how she went from studying biochemistry at McGill University to pharmaceutical sales, then into leadership at 25, and eventually into the early internet era where she joined Medscape/WebMD as an early employee and helped scale revenue from about $20M to $400M+.

You will hear her practical framework for hiring in fast growth environments, how to assess leaders in your first 90 days, when to remove toxic high performers, and why some of the best operators intentionally choose to stay in the number two seat.

What you will learn:

• Why early hires must include future leaders

• The traits Dorothy screens for when hiring sales and commercial talent

• A clear 90 day assessment process for leadership teams

• Why toxicity has to go even if the person produces revenue

• How Dorothy thinks about CEO strength vs CCO strength

• The difference between VC, PE, and public company operating rhythms

• How to preserve culture as headcount scales

• Dorothy’s take on AI in healthcare and where it is already working

Timestamps:

00:00 Dorothy introduced and leadership in high growth companies

00:29 When you know someone is the wrong person on the team

00:54 Why this conversation mattered to Sheetal

01:18 Dorothy’s early career and scaling experience preview

02:38 From pre med to business and pharma sales

03:15 Career day that changed her path

04:05 Why big company sales training matters

05:05 Why startups struggle to train people well

05:51 Becoming a district manager at 25 leading older reps

07:15 Leadership fundamentals and learning accountability

08:34 Why staying at a big company built her foundation

09:44 Lateral moves into marketing and international experience

10:58 Seeing the internet reshape healthcare and taking the leap

11:03 Why WebMD and Medscape felt like the future

12:08 Speeding up healthcare data and decisions via the internet

13:29 Joining Medscape early and loving the startup pace

15:06 Dot com volatility and leading through uncertainty

16:22 The balance between testing and burning cash

18:05 A blunt truth about job security in downturns

19:44 Hiring traits that scale teams in fast growth

21:12 Grit as a requirement in sales and startups

21:37 The 50 percent rule: hire people who can lead others

23:24 Numbers and accountability in commercial talent

24:39 Why she left WebMD and the noncompete lesson

26:19 CEOs do not need to know every job

27:27 The 90 day plan: change thoughtfully and fast

28:19 How Dorothy assesses leaders and teams

29:54 Toxicity has to go even when they are top performers

32:03 Set expectations early to reduce turmoil

33:24 The CEO traits that create loyalty and mission focus

36:11 Strategic discipline and avoiding the goat rodeo

36:53 Why Dorothy chooses to be number two

38:09 The personal cost of being CEO in growth companies

39:21 Work life balance: no guilt and being present

42:15 VC vs PE vs public: sprint marathon treadmill

44:14 Operating differences and resources by company type

46:16 Why she chose several smaller growth stints

48:05 Preserving culture as the company scales

50:09 C suite shifts: revenue plus margins and ops

51:14 What makes a strong executive team

52:29 Why offsites and relationship building matter

53:09 AI and the next chapter of healthcare

55:19 What she is most proud of: people she helped grow

Most people know LabCorp for routine blood work. But under CEO Dave King, the company expanded far beyond basic diagnostics, scaling from about $4B to $14B in revenue while navigating relentless pricing pressure, major acquisitions, and a rapidly changing healthcare landscape.

In this conversation, Dave breaks down what it really takes to scale through M&A, why some deals worked and others missed expectations, and how to lead when decisions draw criticism. He also talks about Theranos, why he stayed quiet publicly, and how the science ultimately caught up. Finally, he shares how LabCorp built a unified, patient first culture across roles ranging from PhDs to couriers and phlebotomists, and why the team’s Covid response became one of his proudest moments.

What you’ll hear in this episode:

-The economics of the lab business and why volume matters

-How Dave went from prosecutor and partner to LabCorp general counsel and then CEO

-Building real compliance culture after a corporate integrity agreement

-The biggest shift when you become CEO and why it takes time to learn the job

-The “lazy with the numbers” moment and how it reshaped his leadership

-LabCorp’s M&A strategy, including Genzyme Genetics and the Covance deal

-Theranos behind the scenes and why LabCorp avoided taking the bait publicly

-Navigating PAMA reimbursement cuts in a high fixed cost model-Succession, stepping away gracefully, and not becoming the “court of appeals”

-How to build culture across a massive, diverse workforce

-Why LabCorp’s Covid response is the moment he’s most proud of

Timestamps:

00:00:00 LabCorp’s transformation and Dave King intro

00:01:10 The scale story: CEO tenure, growth, and deal reality

00:02:06 Early life: DC, Illinois, Berkeley

00:03:10 Princeton, public affairs, Near Eastern studies

00:03:32 Teaching high school and why he chose law

00:04:40 Traditional legal career: clerk, prosecutor, big firm

00:05:53 Meeting LabCorp through investigations

00:06:31 Why he moved in house and what changed personally

00:08:15 Compliance culture shift and staffing legal and compliance

00:09:23 Becoming CEO later in life and why that helped

00:11:31 The real CEO job versus ops leadership

00:13:09 “You’re lazy with the numbers” and the habit that fixed it

00:15:54 Strategy pivot: pricing pressure and broadening the revenue base

00:18:17 Genzyme Genetics and building leadership in genetics

00:20:23 Integration philosophy: one LabCorp culture

00:22:42 Deals you do not do and what he regrets not bolstering

00:24:52 Theranos: investor distraction, science reality, and why he stayed quiet

00:30:50 The Covance deal: why it mattered and the precision medicine thesis

00:33:10 Why Covance under delivered and what he learned

00:35:13 Leadership means decisions plus criticism

00:36:03 PAMA cuts: what happens in high fixed cost economics

00:39:06 Retirement planning and timing

00:40:35 Succession and stepping away gracefully

00:43:29 Not the court of appeals: how to support the new CEO

00:44:35 Culture across roles: scientists, couriers, phlebotomists

00:48:09 Senior team stability and deliberate hiring

00:49:47 Proud moments: the Covid response and the team’s intensity

00:52:19 Closing thoughts

Many investors and operators call Mettler Toledo one of the best run companies in the world.

In season 1, episode #3 of No Spotlight Needed, Sheetal sits down with Bill Donnelly, longtime CFO of Mettler Toledo, to unpack the leadership habits and cultural systems behind decades of consistent execution.

Bill shares how his Jesuit foundation shaped his approach to communication, empathy, and decision making, why culture gets reinforced in moments of crisis, and what it really takes to sustain continuous improvement.

He also reflects on the CEO-CFO relationship, how the Great Financial Crisis allowed them to move even faster, and why his next chapter is focused on mission-based education and social innovation at John Carroll University.

Timestamps:

Introduction to Bill Donnelly and Mettler Toledo (00:00:00) Overview of Mettler Toledo’s reputation, Bill Donnelly’s leadership, and his impact on company culture.

Early Life and Family Background (00:02:38) Bill’s upbringing in New York and Chicago, Irish heritage, and influence of his grandfather.

Education and Jesuit Foundation (00:05:20) Decision to attend John Carroll University, Jesuit values, and how education shaped his thinking and communication.

Meeting His Wife and Early Career (00:11:28) Meeting his wife at John Carroll, early married life, and starting his career at Price Waterhouse.

Lessons from Price Waterhouse (00:12:35) Technical and leadership skills developed, importance of international experience, and mentorship.

First CFO Role at Elson Bailey (00:14:35) Transition to Elson Bailey, IPO experience, building company functions, and challenges of establishing culture.

Joining Mettler Toledo and Swiss Culture (00:18:23) Introduction to Mettler Toledo, meeting Robert Sperry, and contrast between Swiss structure and previous roles.

Transition to Operational Role in the US (00:21:10) Moving back to the US, running global inspection and lab businesses, and personal/professional development.

Whistleblower Crisis at Mettler Toledo (00:22:51) Details of the whistleblower investigation, Bill’s return to stabilize the company, and impact on culture.

Restoring Confidence and Leadership Tone (00:28:33) Setting the tone at the top, restoring trust, and reinforcing company values post-crisis.

Family Crisis and Career Commitment (00:30:15) Wife’s cancer diagnosis, prioritizing family, and decision to remain at Mettler Toledo.

CEO-CFO Leadership Dynamics (00:33:53) Relationship with CEOs Robert and Olivier, complementary skills, and building a strong leadership team.

Navigating the Great Financial Crisis (00:40:01) Responding to the 2008 crisis, rapid cost-cutting, organizational resilience, and lessons learned.

Continuous Improvement and Company Culture (00:46:33) How continuous improvement, humility, and trust drove Mettler Toledo’s long-term success.

Retirement Decision and Succession (00:51:16) Reasons for retiring in 2018, preparing successors, and balancing personal and professional life.

Mission at John Carroll University (00:53:53) Post-retirement focus on John Carroll University, leadership in education, and fostering social innovation.

Conclusion and Reflections (00:58:24) Final thoughts on leadership, legacy, and gratitude for the opportunity to share his journey.

In Season 1, episode #2 of No Spotlight Needed, host Sheetal Prasad sits down with Erica Rogers, board director and former CEO, to unpack the real story behind building and leading in MedTech, from her early career at Boston Scientific, to founding startups, navigating a company failure, and scaling Silk Road Medical through the public markets.

Erica shares what it’s actually like when a clinical trial fails, how to lead a board to the hard decision to shut the doors, and why culture is not a poster on the wall, it’s a daily practice. She also explains the CEO reality nobody trains you for: making big calls with imperfect information, managing strong board personalities, and staying focused on building value.

You’ll also hear the origin story of “Cartwheel Culture”, the framework Erica used to build a team people loved waking up to be a part of.

Timestamps:

Early Career and Upbringing (00:01:01) Erica’s childhood in San Diego, artistic background, and early influences.

Big Company Training at Boston Scientific (00:03:12) Value of large company experience and cross-functional training.

Transition to Entrepreneurship (00:04:51) Leaving Boston Scientific, being recruited, and the decision to pursue more impactful work.

Entrepreneur in Residence and VizioJen (00:06:36) Role as entrepreneur in residence, partnering with Reza, and founding VizioJen in ophthalmology.

Starting from Scratch and Early Startup Roles (00:08:08) Challenges of starting a company, learning new fields, and handling all responsibilities in a small team.

VizioJen’s Exit and Personal Decisions (00:10:35) VizioJen’s $400M exit, personal reasons for leaving, and desire to start again.

Founding Alex Medical and the Challenge of Failure (00:11:24) Formation of Alex Medical, novel ENT devices, and the excitement of new interventional procedures.

Clinical Trial Failure and Company Closure (00:13:41) Failed clinical trial, economic downturn, and the difficult decision to shut down Alex Medical.

Aftermath of Failure and Lessons Learned (00:16:40) Emotional impact of failure, value of company culture, and support from the team during wind-down.

Navigating Doubt and Nonprofit Work (00:17:41) Dealing with founder doubt, working at Medicine360, and redefining success after failure.

Joining Silk Road Medical (00:20:17) Recruitment to Silk Road, initial reluctance, and the principle of failing fast.

Silk Road’s Early Culture and Team Rebuilding (00:22:36) Poor initial company culture, tough decisions, and rebuilding the team with a new vision.

Hiring Strategy and Paradigm Shifts (00:25:16) Prioritizing talent, bringing in new perspectives, and the importance of domain expertise in key roles.

Managing a Hands-On Board (00:29:14) Challenges of a strong, involved board, and learning that the company belongs to shareholders.

IPO vs. Acquisition Decision (00:32:31) Weighing public offering against selling, emotional and practical considerations, and the drive to change medicine.

Life as a Public Company CEO (00:37:10) Shifting responsibilities post-IPO, increased focus on investor relations, and reliance on a strong team.

Reimbursement Challenges and Market Uncertainty (00:38:40) CMS reimbursement changes, market confusion, and the impact on Silk Road’s growth outlook.

Retirement Decision and Succession (00:41:28) Achieving full coverage, planning retirement, and the optics of CEO transition amid business uncertainty.

Reflecting on Silk Road’s Success (00:45:27) Boston Scientific’s acquisition, public perception of her exit, and pride in the company’s achievements.

Cartwheel Culture and Company Values (00:46:22) Origin and meaning of “cartwheel culture,” its impact on team spirit, and embedding values in daily work.

Next Chapter: Board Work and Personal Goals (00:50:23) Life after Silk Road, board roles, mentoring, community building, and pursuing personal passions like piano.

Closing Remarks (00:52:14) Final thanks, reflections on impact, and advice for future entrepreneurs.

In Episode 1 of Season 1 of No Spotlight Needed, Sheetal sits down with Keith Grossman, a four time CEO and MedTech operator known for building and turning around companies through focus, urgency, and team first culture.

Keith walks through the arc of his career, including becoming CEO of Thoratec at 35 with the company nearly out of cash, engineering a major merger to secure future technology, leading through the personal and organizational tragedy of 9/11, stepping away at the right time, and later returning to reignite execution and regain market share.

They also dig into what makes boards helpful instead of harmful, why CEOs should not try to manage boards like a management team, and what Keith believes is the most repeatable lever in leadership: recruiting great people and creating energized cultures that win.

What you’ll learn

• How Keith prioritized when the company had almost no cash and everything was urgent

• Why he pushed a merger even while winning near term market share

• Leading through loss and keeping an organization steady in a crisis

• The difference between growth through new customers vs getting to standard of care

• Why decisive leadership and fewer projects often unlock performance fast

• Board best practices for CEOs: collaboration, education, and honest dialogue

• Keith’s “leadership superpower”: recruiting and building high performance cultures

Timestamps:

00:00 Cold open: outcomes, what boards should do, and leadership focus

01:03 Intro to Keith: 4 time CEO, major exits, non linear path

02:16 Welcome + rapid fire begins

02:41 Where Keith was born and raised02:50 Parents and early influences

03:13 “Nothing happens until somebody sells something”

03:46 College path: Miami of Ohio to Ohio State04:17 Athlete, music, and team sports as leadership training

05:46 First jobs and earning early

06:30 Why Thoratec at 35 with $1M left and a massive challenge

08:56 Early priorities: capital raise, team, manufacturing, commercialization

10:44 Building the market while the plane is in the air

11:34 The hard truth: bridge to transplant market was too small

13:36 The merger strategy and why it worked

15:33 Negotiating control and why the deal was possible

17:37 The roller coaster: 9 11 and losing COO Tom Burnett on Flight 93

19:41 Leading through crisis: restructure and communicate immediately

21:40 Company mission and recovery

22:43 Why Keith initiated succession planning during a “magical” period

25:10 Results from first run at Thoratec

26:14 Joining TPG and learning the industry from the other side

28:34 Why Keith didn’t want to be a venture capitalist

29:08 Operator at heart

29:19 Taking the CEO role at Conceptus: why it was compelling

31:49 Diagnosis: growth stalled due to execution and culture

32:41 Fixing the model: standard of care vs chasing new customers

35:03 Fixing culture: urgency, analytics, accountability

36:04 Shrinking the sales force and returning to growth

37:33 The 1.1B exit and what came next

40:09 Watching Thoratec round trip and competitor pressure

43:04 The board asks Keith to return44:07 Coming back: moving faster with a ready playbook

45:49 Turnaround principle: vision, speed, and top down focus

47:55 Cutting initiatives, reorganizing leadership, reasserting customer value

49:21 Momentum returns fast50:32 The 3.4B sale and why consolidation made sense

53:39 Retirement, board work, and the next chapter

55:03 Nevro turnaround attempt and what Covid changed

01:01:32 Why the market may not have come back

01:03:29 Single product risk when growth stops

01:08:04 CEO advice on working with boards

01:11:22 What Keith is most proud of

01:13:31 Keith’s leadership “superpower”: recruiting + energized cultures

01:15:17 Closing

Welcome to No Spotlight Needed, a leadership podcast that explores the human stories behind extraordinary executives.

Hosted by Sheetal Prasad, an equity investor with 25+ years of experience analyzing business models and assessing management teams, this show goes beyond the surface. These conversations focus on what rarely shows up in headlines or earnings calls: formative moments, values, decision making frameworks, and the principles that shape great leadership.

This 90 second trailer is a montage from the first five episodes of Season 1, featuring lessons on leadership under pressure, culture that actually performs, board dynamics, and the real tradeoffs leaders make when the stakes are high.

Season 1 lineup

1. Keith Grossman, Retired CEO of Thoratec, Conceptus & Nevro, Board Member

2. Erica Rogers, Retired CEO of Silk Road Medical, Entrepreneur, Board Member, 

3. Bill Donnelly, Retired CFO of Mettler Toledo, Board Member

4. David King, Retired Executive Chairman and CEO of Labcorp

5. Dorothy Gemmell, 5X Chief Commercial Officer and President of GoodRx, Capsule, WebMD

Trailer is live today, Thursday, January 8, 2026.Episode 1 with Keith Grossman goes live tomorrow, Friday, January 9, 2026.

Listen, follow, and subscribe!